RF
NMTR

Rollins Financial’s 9 Meters Biopharma NMTR Stock Holding History

Rollins Financial’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$11K Buy
+500
New +$12.3K ﹤0.01% 102

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rollins Financial's NMTR Position: Q2 2021 in Review

Rollins Financial opened a new position in 9 Meters Biopharma (NMTR) in Q2 2021: 500 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #102 among its holdings.

99 funds tracked by Wall St. Rank hold NMTR as of Q2 2021.

  • Rollins Financial held 500 shares of 9 Meters Biopharma worth $11K as of Q2 2021.
  • 9 Meters Biopharma was a new Rollins Financial position in Q2 2021.
  • 9 Meters Biopharma made up ﹤0.01% of Rollins Financial's portfolio in Q2 2021, its #102 holding.
  • 99 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2021.

Based on Rollins Financial's 13F filing for Q2 2021, filed 4 Aug 2021.